Literature DB >> 15160292

Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child.

Satoru Sakazume1, Kazuo Obata, Etsurou Takahashi, Atsunori Yoshino, Nobuyuki Murakami, Ryoich Sakuta, Takayasu Murai, Toshiro Nagai.   

Abstract

UNLABELLED: A 13-year-old Japanese boy with pituitary prolactinoma whose growth had been retarded for more than 2 years was treated with bromocriptine alone for 140 weeks. After treatment, the serum level of prolactin, which was 1200 ng/ml before treatment, returned to normal and the pituitary tumour seen on the initial brain MRI had rapidly decreased in size after 16 weeks of treatment. Thereafter, his height improved (from -2.1 to -1.7 SDS).
CONCLUSION: the favourable response obtained in this patient implies that bromocriptine monotherapy can be an effective first-line treatment for children with prolactinoma. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160292     DOI: 10.1007/s00431-004-1454-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.

Authors:  L D George; N Nicolau; M F Scanlon; J S Davies
Journal:  Clin Endocrinol (Oxf)       Date:  2000-11       Impact factor: 3.478

2.  Pergolide as primary therapy for macroprolactinomas.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

3.  Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.

Authors:  N Pontikides; G E Krassas; E Nikopoulou; T Kaltsas
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

Review 4.  Prolactinomas in children and adolescents--consequences in adult life.

Authors:  L H Duntas
Journal:  J Pediatr Endocrinol Metab       Date:  2001       Impact factor: 1.634

Review 5.  Current management of prolactinomas.

Authors:  P Nomikos; M Buchfelder; R Fahlbusch
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

6.  Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.

Authors:  A Colao; S Loche; M Cappa; A Di Sarno; M L Landi; F Sarnacchiaro; G Facciolli; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

7.  Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches.

Authors:  H L Fideleff; H R Boquete; A Sequera; M Suárez; P Sobrado; A Giaccio
Journal:  J Pediatr Endocrinol Metab       Date:  2000-03       Impact factor: 1.634

8.  Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery.

Authors:  M D Partington; D H Davis; E R Laws; B W Scheithauer
Journal:  J Neurosurg       Date:  1994-02       Impact factor: 5.115

9.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  Pituitary adenomas in childhood and adolescence.

Authors:  L A Kane; M C Leinung; B W Scheithauer; E J Bergstralh; E R Laws; R V Groover; K Kovacs; E Horvath; D Zimmerman
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

  10 in total
  2 in total

1.  Prolactinomas in children under 14. Clinical presentation and long-term follow-up.

Authors:  Yang Liu; Yong Yao; Bing Xing; Wei Lian; Kan Deng; Ming Feng; Renzhi Wang
Journal:  Childs Nerv Syst       Date:  2015-03-15       Impact factor: 1.475

2.  Cabergoline Effectively Induced Remission of Prolactinoma in a 9-year-old Japanese Boy.

Authors:  Hitomi Sano; Masayoshi Takigami; Tetsuo Ogino; Keita Morioka; Tomoshiro Ito; Akira Sudo; Naoki Fukushima
Journal:  Clin Pediatr Endocrinol       Date:  2009-05-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.